Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Elongin C pseudogene 21 (ELOCP21) is classified as a pseudogene related to the elongin C gene (TCEB1), which is a component of the elongin complex that regulates the elongation phase of transcription by RNA polymerase II[6][4]. As a pseudogene, ELOCP21 does not encode a protein and has no established role as a drug target, biomarker, or in human disease. The functional parent gene, elongin C (ELOC/TCEB1), participates in regulating transcription and is part of several ubiquitin ligase complexes, but ELOCP21 itself has no demonstrated function in these processes[1][8][4][6]. There is no evidence that ELOCP21 is a molecular target relevant to therapeutics, diagnostics, or pathophysiology. Its nomenclature is sometimes confused with functional homologs, but it should be clearly distinguished as a non-coding pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Elongin C pseudogene 21 (ELOCP21).